Objective: To summarize the histological and clinical characteristics of 40 cases with Burkitt's and Burkitt-like lymphoma in children, to evaluate the effects of treatment with international regimen, and to explore the treatment-related complications and prognostic factors.

Methods: Forty patients with Burkitt's and Burkitt-like lymphoma were registered in Beijing Children Hospital from Feb 2003 to Apr 2006. The diagnosis was confirmed by histology and immunohistochemistry of biopsy, and clinical staging by the examination of imaging, cerebrospinal fluid and bone marrow based on St. Jude system. Intensive, short-term chemotherapy witch was modified from LMB89 protocol was given to the patients.

Results: Of the 40 patients, 30 were diagnosed as Burkitt's lymphoma (BL) and 10 as Burkitt-like lymphoma (BLL). Antibody against Epstein-Barr virus (EBV-Ab) was positive in 19 cases at diagnosis, only 7 of the patients were positive for EBER. Thirty-three of the cases were male and 7 female (M:F = 4.7:1); the median age was 6 years 9 months. The most frequently seen clinical characteristics were abdominal masses and surgical abdomen. Nine cases were at stage I - II and 31 cases at stage III - IV at diagnosis; CNS was involved in 4 cases and bone marrow in 2 cases. The courses of treatment were approximately 2 - 8 months. All the patients were followed up, the median follow-up period was 22.6 months. After chemotherapy, 35 patients (88.7%) were still alive during the one-year follow-up. The 3-year event-free survival (EFS) rate was 81.8%. Major toxicity was myelosuppression and mucositis. Stage III to IV of myelosuppression occurred in the most patients with unresected tumor and CNS-involvement. Of 5 patients who died, 2 died of infection, 2 died of lymphoma progression during chemotherapy, and 1 died of relapse.

Conclusion: Burkitt's and Burkitt-like lymphoma are the most common NHL in children with rapid clinical process. Outcome was greatly improved by current intensive, short-term chemotherapy regimen, the 3-year EFS was 81.8% including the patients who were in advanced stage. Childhood lymphoma with short clinical history, stage IV and residual disease after 3 months of therapy are associated with poor prognosis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

burkitt's burkitt-like
16
burkitt-like lymphoma
16
clinical characteristics
8
patients
8
bone marrow
8
intensive short-term
8
short-term chemotherapy
8
cases stage
8
stage iii
8
cases
7

Similar Publications

Various aggressive lymphomas entities have been associated with immunodeficiency. To provide further evidence that also MYC-negative high-grade B-cell (formerly Burkitt-like) lymphoma with 11q aberrations comprises an immunodeficiency-related subtype, we here conducted a comprehensive pathological and genetic workup of a 25-year-old patient with this type of lymphoma and simultaneous papillary renal cell carcinoma. The patient developed both malignancies following extensive childhood immunosuppression and a kidney transplant.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on primary lymphoid neoplasms in the urinary tract and male genital organs, which are rare and make up less than 5% of extranodal lymphomas.
  • Researchers analyzed cases diagnosed from 2005 to 2020, examining pathology slides from 11 patients, predominantly middle-aged, finding a female predominance in urinary bladder and ureter lymphomas.
  • The findings confirm that diffuse large B-cell lymphoma (DLBCL) is the most common subtype, but emphasize the importance of thorough classification and diagnosis using techniques like immunohistochemistry to accurately identify various lymphoma types.
View Article and Find Full Text PDF
Article Synopsis
  • - The study examines angioimmunoblastic T-cell lymphoma (AITL) cases with a focus on their clinical, pathological, and immunophenotypic characteristics, as well as the differential diagnosis involving B-cell proliferation or neoplasms.
  • - Eight cases from a hospital in China were analyzed, revealing one case of AITL with diffuse large B-cell lymphoma (DLBCL) and seven cases of AITL with B-cell proliferation, with an average patient age of 58 years.
  • - The findings highlight distinct histological features and tumor behavior in AITL with B-cell involvement, suggesting that a combination of clinical, morphological, and molecular analyses is essential for accurate diagnosis.
View Article and Find Full Text PDF
Article Synopsis
  • Monomorphic post-transplant lymphoproliferative disorder (mPTLD) is a significant health risk after solid organ transplants, with challenges in balancing treatment intensity and risks like infection and organ rejection.* -
  • A study analyzed 56 children with mPTLD treated with low-intensity therapies in the UK and Spain, finding that 92.8% survived for one year, despite 78.6% presenting with advanced disease.* -
  • The results indicate that R-COP, a low-dose chemotherapy, is an effective initial treatment, with escalation to more aggressive approaches beneficial for those who do not adequately respond.*
View Article and Find Full Text PDF

Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.

PLoS Pathog

April 2024

Department of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin Madison, Madison, Wisconsin, United States of America.

Epstein-Barr virus (EBV) is an important cause of human lymphomas, including Burkitt lymphoma (BL). EBV+ BLs are driven by Myc translocation and have stringent forms of viral latency that do not express either of the two major EBV oncoproteins, EBNA2 (which mimics Notch signaling) and LMP1 (which activates NF-κB signaling). Suppression of Myc-induced apoptosis, often through mutation of the TP53 (p53) gene or inhibition of pro-apoptotic BCL2L11 (BIM) gene expression, is required for development of Myc-driven BLs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!